Browse RXFP2

Summary
SymbolRXFP2
Namerelaxin/insulin-like family peptide receptor 2
Aliases GREAT; GPR106; INSL3R; RXFPR2; LGR8; leucine-rich repeat-containing G protein-coupled receptor 8; LGR8.1; G ......
Chromosomal Location13q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein.
Domain PF00001 7 transmembrane receptor (rhodopsin family)
PF00057 Low-density lipoprotein receptor domain class A
PF13855 Leucine rich repeat
Function

Receptor for relaxin. The activity of this receptor is mediated by G proteins leading to stimulation of adenylate cyclase and an increase of cAMP. May also be a receptor for Leydig insulin-like peptide (INSL3).

> Gene Ontology
 
Biological Process GO:0001556 oocyte maturation
GO:0006140 regulation of nucleotide metabolic process
GO:0006164 purine nucleotide biosynthetic process
GO:0006171 cAMP biosynthetic process
GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger
GO:0007188 adenylate cyclase-modulating G-protein coupled receptor signaling pathway
GO:0007189 adenylate cyclase-activating G-protein coupled receptor signaling pathway
GO:0007193 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway
GO:0007281 germ cell development
GO:0007292 female gamete generation
GO:0007548 sex differentiation
GO:0008406 gonad development
GO:0008584 male gonad development
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009187 cyclic nucleotide metabolic process
GO:0009190 cyclic nucleotide biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0009994 oocyte differentiation
GO:0021700 developmental maturation
GO:0022412 cellular process involved in reproduction in multicellular organism
GO:0030799 regulation of cyclic nucleotide metabolic process
GO:0030801 positive regulation of cyclic nucleotide metabolic process
GO:0030802 regulation of cyclic nucleotide biosynthetic process
GO:0030804 positive regulation of cyclic nucleotide biosynthetic process
GO:0030808 regulation of nucleotide biosynthetic process
GO:0030810 positive regulation of nucleotide biosynthetic process
GO:0030814 regulation of cAMP metabolic process
GO:0030816 positive regulation of cAMP metabolic process
GO:0030817 regulation of cAMP biosynthetic process
GO:0030819 positive regulation of cAMP biosynthetic process
GO:0045137 development of primary sexual characteristics
GO:0045981 positive regulation of nucleotide metabolic process
GO:0046058 cAMP metabolic process
GO:0046390 ribose phosphate biosynthetic process
GO:0046546 development of primary male sexual characteristics
GO:0046661 male sex differentiation
GO:0048469 cell maturation
GO:0048477 oogenesis
GO:0048599 oocyte development
GO:0048608 reproductive structure development
GO:0052652 cyclic purine nucleotide metabolic process
GO:0061458 reproductive system development
GO:0072522 purine-containing compound biosynthetic process
GO:1900371 regulation of purine nucleotide biosynthetic process
GO:1900373 positive regulation of purine nucleotide biosynthetic process
GO:1900542 regulation of purine nucleotide metabolic process
GO:1900544 positive regulation of purine nucleotide metabolic process
GO:1901293 nucleoside phosphate biosynthetic process
Molecular Function GO:0016500 protein-hormone receptor activity
GO:0017046 peptide hormone binding
GO:0033218 amide binding
GO:0042277 peptide binding
GO:0042562 hormone binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04080 Neuroactive ligand-receptor interaction
Reactome R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-418555: G alpha (s) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-444821: Relaxin receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolRXFP2
Namerelaxin/insulin-like family peptide receptor 2
Aliases GREAT; GPR106; INSL3R; RXFPR2; LGR8; leucine-rich repeat-containing G protein-coupled receptor 8; LGR8.1; G ......
Chromosomal Location13q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RXFP2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolRXFP2
Namerelaxin/insulin-like family peptide receptor 2
Aliases GREAT; GPR106; INSL3R; RXFPR2; LGR8; leucine-rich repeat-containing G protein-coupled receptor 8; LGR8.1; G ......
Chromosomal Location13q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RXFP2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRXFP2
Namerelaxin/insulin-like family peptide receptor 2
Aliases GREAT; GPR106; INSL3R; RXFPR2; LGR8; leucine-rich repeat-containing G protein-coupled receptor 8; LGR8.1; G ......
Chromosomal Location13q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RXFP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.5430.135
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.9540.52
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-2.2890.168
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.7090.0474
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RXFP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolRXFP2
Namerelaxin/insulin-like family peptide receptor 2
Aliases GREAT; GPR106; INSL3R; RXFPR2; LGR8; leucine-rich repeat-containing G protein-coupled receptor 8; LGR8.1; G ......
Chromosomal Location13q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RXFP2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRXFP2
Namerelaxin/insulin-like family peptide receptor 2
Aliases GREAT; GPR106; INSL3R; RXFPR2; LGR8; leucine-rich repeat-containing G protein-coupled receptor 8; LGR8.1; G ......
Chromosomal Location13q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RXFP2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RXFP2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRXFP2
Namerelaxin/insulin-like family peptide receptor 2
Aliases GREAT; GPR106; INSL3R; RXFPR2; LGR8; leucine-rich repeat-containing G protein-coupled receptor 8; LGR8.1; G ......
Chromosomal Location13q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RXFP2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRXFP2
Namerelaxin/insulin-like family peptide receptor 2
Aliases GREAT; GPR106; INSL3R; RXFPR2; LGR8; leucine-rich repeat-containing G protein-coupled receptor 8; LGR8.1; G ......
Chromosomal Location13q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RXFP2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRXFP2
Namerelaxin/insulin-like family peptide receptor 2
Aliases GREAT; GPR106; INSL3R; RXFPR2; LGR8; leucine-rich repeat-containing G protein-coupled receptor 8; LGR8.1; G ......
Chromosomal Location13q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RXFP2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRXFP2
Namerelaxin/insulin-like family peptide receptor 2
Aliases GREAT; GPR106; INSL3R; RXFPR2; LGR8; leucine-rich repeat-containing G protein-coupled receptor 8; LGR8.1; G ......
Chromosomal Location13q12.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RXFP2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.